Q32 Bio Inc. (QTTB)
NASDAQ: QTTBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 7.82 -2.11%
QTTB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $237.86M
- P/E (TTM)
- 2.54
- EPS (TTM)
- $3.15
- Dividend yield
- None
- 52-week range
- 1.91 – 23.57
- Day range
- 7.83 – 8.07
- Volume / Avg
- 567.57K / 1.37M
- Beta
- —
- Shares outstanding
- 29.77M
52-week range
QTTB stock today
On Oct 7, QTTB ended the session at $7.99, shedding $0.12 (1.48%), versus the S&P 500's 0.22% decline. Trading was light, with 567.57K shares changing hands, about 41% of the average daily volume. Shares are 66.1% below their 52-week high of $23.57, set on Jul 14, 2026 and 319.4% above the 52-week low of $1.91, in the middle of the past year's range.
QTTB is up 140.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 217.1%. Q32 Bio trades at 2.5x its trailing twelve-month earnings per share of $3.15.
Summary generated from market data by MetaCap's automated system. Methodology
About Q32 Bio
Company profileQ32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jodie Pope Morrison
- Headquarters
- Waltham, MA
- Employees
- 22
- IPO year
- 2018
- Website
- q32bio.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$39.60+395.62%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Q32 Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CAMPCAMP4 Therapeutics Corporation | 3.84 | -3.03% | $240.97M | vs QTTB |
| AKBAAkebia Therapeutics Inc. | 0.8734 | -0.58% | $242.02M | vs QTTB |
| PYXSPyxis Oncology Inc. | 2.01 | -0.49% | $240.11M | vs QTTB |
| VOGXVogenx Inc | 16.16 | -1.40% | $240.06M | vs QTTB |
| VCREVicore Pharma Holding AB ADR | 8.66 | -2.74% | $243.90M | vs QTTB |
| LFCRLifecore Biomedical Inc. | 6.44 | -0.15% | $244.11M | vs QTTB |
| SLGLSol-Gel Technologies Ltd. | 71.95 | -4.88% | $235.55M | vs QTTB |
| SIGASIGA Technologies Inc. | 3.26 | -0.91% | $234.23M | vs QTTB |
Indexes, lists and sector
Q32 Bio stock FAQ
What is Q32 Bio's stock price today?
QTTB last traded at $7.99 as of Oct 7, 4:00 PM EDT, down 1.48% on the day. Prices are delayed at least 15 minutes.
Does Q32 Bio pay a dividend?
No. Q32 Bio does not currently pay a regular cash dividend.
What is QTTB's P/E ratio?
QTTB trades at a trailing P/E ratio of 2.54.
Who is Q32 Bio's CEO?
Ms. Jodie Pope Morrison is the chief executive officer of Q32 Bio Inc., which has about 22 employees.
Has QTTB ever split its stock?
Yes. The most recent QTTB stock split was a 1-for-18 split on Mar 26, 2024.
What is the QTTB 52-week high?
The 52-week high for QTTB is $23.57 and the 52-week low is $1.91. The stock is currently 66.1% below its high.